Polymyositis clinical trials

Explore recruiting polymyositis clinical trials.

Recruiting polymyositis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Polymyositis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants receiving Standard of Care

Italy, Poland, Czechia, Sweden, Spain, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID): a single-center, randomized, double-blind and placebo-controlled phase 2 clinical basket trial

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS)

Bulgaria, Sweden, Hungary, Poland, France, Belgium +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Denmark, Belgium, Italy, Sweden, Netherlands, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

C0251010 - A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)

Bulgaria, Hungary, Sweden, Italy, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled Phase II proof of concept study evaluating efficacy and safety of Upadacitinib in patients with idiopathic inflammatory myopathies after withdrawal of intravenous immunoglobulins (IVIG) (IVIG-Spare)

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

Polymyositis trials by city

Polymyositis in Toronto Polymyositis in Vancouver Polymyositis in Montreal Polymyositis in Calgary Polymyositis in Edmonton Polymyositis in Ottawa Polymyositis in Winnipeg Polymyositis in Quebec City Polymyositis in Hamilton Polymyositis in Kitchener Polymyositis in London Polymyositis in Halifax Polymyositis in New York Polymyositis in Los Angeles Polymyositis in Chicago Polymyositis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease